MAP2K4 inhibitors (Astex Pharmaceuticals)

N/A

Report date: 2025/06/11 10:31:11
NME

Base Information

Drug NameMAP2K4 inhibitors (Astex Pharmaceuticals)
Drug Alias NameN/A
ClassificationSmall molecules
Mechanisms of ActionAnticancer protein kinase inhibitorsDual specificity mitogen-activated protein kinase kinase 4 inhibitors
TargetsDual specificity mitogen-activated protein kinase kinase 4
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAstex Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesAstex Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A